|
| Ibalizumab治疗耐多药HIV-1感染的研究进展 |
| Research advances of ibalizumab in the treatment of multidrug-resistant HIV-1 infection |
| |
| DOI：10.3969/j.issn.1007-8134.2022.02.016 |
| 中文关键词: ibalizumab 耐多药 抗病毒活性 单克隆抗体 交叉耐药 药代动力学特性 临床研究 |
| 英文关键词: ibalizumab multidrug-resistance antiviral activity monoclonal antibody cross-resistance pharmacokinetic property clinical trial |
| 基金项目:贵州省卫生健康委科学技术基金（2019-1-082）；贵州省科技计划项目（[2020]1Y299）；国家自然科学基金（82060123）
[作者单位] 550004?贵阳，贵州医科大学附属医院感染科（李宏、万艳） |
|
| 摘要点击次数: 759 |
| 全文下载次数: 0 |
| 中文摘要: |
| [摘要] Ibalizumab是一种人源化免疫球蛋白G4单克隆抗体，其在阻断HIV-1进入CD4+ T淋巴细胞的同时，可保持人体正常免疫功能。鉴于此，临床逐步将ibalizumab与其他抗反转录病毒药物联合应用于治疗耐多药HIV-1感染，相关研究已经取得了较大进展。目前，ibalizumab是第一个被美国FDA批准用于治疗HIV-1感染的单克隆抗体，有望成为治疗耐多药HIV-1感染的新选择。本文综述了ibalizumab治疗成人耐多药HIV-1感染的药理学特性及临床疗效，为耐多药HIV-1感染的治疗提供参考。 |
| 英文摘要: |
| [Abstract] Ibalizumab, a humanized immunoglobulin G4 monoclonal antibody, blocks HIV-1 entry into CD4+ T lymphocytes while preserving normal immune function of human body. Thereforem ibalizumab in combination with other antiretroviral(s) is indicated in clinical treatment of multidrug-resistant HIV-1 infection, and has achieved great progress in related research. Ibalizumab is the first monoclonal antibody approved by the U.S. FDA for the treatment of HIV-1 infection and provided a new choice for the treatment of multi drug-resistant HIV-1 infection. This article reviews the pharmacological properties and clinical efficacy of ibalizumab in the treatment of adult multidrug-resistant HIV-1 infection, and provides references for the treatment of multidrug-resistant HIV-1 infection. |
|
HTML
查看全文
下载PDF阅读器 |
| 关闭 |